Endoceuticals
Bioregulator-based therapeutics formulated for prescription clinical use.
The clinical tier of bioregulatory medicine.
Endoceuticals are bioregulator-based therapeutic preparations formulated for prescription clinical use under appropriate medical supervision. They are dispensed through licensed pharmacy channels — including 503A pharmacy compounding for patient-specific preparations and FDA-pathway preparations for indication-approved therapeutics.
They are intended for clinically supervised endogenic intervention — the treatment of diagnosed conditions, the management of chronic dysregulation, and the operation of structured longevity protocols where clinical oversight, dose individualization, and outcome measurement are appropriate.
Two regulatory pathways.
Endoceuticals reach clinical practice through two complementary distribution pathways. The first is 503A pharmacy compounding, which permits patient-specific preparation by licensed compounding pharmacies under the prescribing authority of a licensed clinician. The second is the FDA approval pathway, through which compositions of matter and methods-of-use are advanced toward indication-specific approval as conventional pharmaceutical preparations.
Both pathways are governed by the same regulatory standards applied to any pharmaceutical preparation: GMP manufacturing, documented chemistry-manufacturing-controls, indication-specific evidence, and post-market surveillance.
Diagnosed conditions and supervised protocols.
The endoceutical tier is appropriate for diagnosed clinical conditions, acute or escalating presentations requiring therapeutic intervention, structured longevity protocols where biomarker-driven titration is clinically warranted, and chronic-condition management where unsupervised opticeutical use is insufficient.
Endoceutical access requires evaluation by a licensed clinician qualified to prescribe and supervise the relevant therapeutic protocol.